Robert Half Just Ripped 22%, And Every Analyst Target Says You're Wrong

Let's get the scoreboard straight before anyone tries to sell you a story. Robert Half (RHI) closed up nearly 9% on October 22 after its Q3 report, then gapped right up to a hair under $46 on October 23 — sitting a stone's throw from its 52-week high of $46.70. Per the desk's own snapshot as of today, the stock is at $45.87, up 21.74% on the day, up roughly 28% on the month, and up ~69% year-to-date.

That is a stock that has decided to run. The question is whether the street agrees it deserves to.

Here's the thing that makes this setup interesting, and not in the way the premarket headlines suggest. The analysts who were supposed to be cheering? They're mostly telling you to get off the bus.

The Report That Started It All

The October 22 earnings were genuinely a decent print, no question. EPS of $0.49 beat consensus by two cents. Net income landed near $49.9M. And for the first time since 2022, Talent Solutions returned to year-over-year growth — up 2%, with US up +3% and non-US down −1%, permanent placement leading at +6%. Contract talent actually lagged at +1%, and non-US Talent Solutions slipped 1%.

The first year-over-year jump in quarterly EPS since 2022, up 14%, is a nice line to live with. Q4 guidance is constructive too: revenue of $1.285B–$1.385B and EPS of $0.36–$0.46 at the midpoint, implying roughly 3% top-line and 30% EPS growth. Management is clearly trying to convince you the staffing cycle is bottoming.

But "bottoming" and "near a 52-week high" are two very different sentences, and everyone in this room should know the difference.

The Analyst Disconnect Is The Real Story

Now here's where it gets funny. The sell-side names that lit up the tape this week — BMO and Truist both to $50, Baird to $53, JPMorgan to $45 — those are the bullish outliers. The consensus across aggregators tells a different tale: medians clustering somewhere between $30.50 and $38.50. Goldman kept its Sell rating and raised its target from $29 to $33. UBS is sitting at $20.

The desk's own target figure sits at $37.89.

Think about what that means. Wall Street did its homework months ago, priced this stock into a soft labor market, and is now watching it rip 22% on a day without a single new fundamental reason to justify it. The earnings beat was real. The guidance was fine. But the multiples do the talking: P/E at 37.78, and a forward P/E of 23.2 — not cheap for a staffing firm whose revenue is still down roughly 2.4% year-over-year and whose operating margin is a thin 1.36%.

What's Actually Driving The Tape

Two narratives are fighting for the wheel here, and neither is clean.

The bulls have a legitimate thesis: cyclical inflection in core staffing demand, Protiviti compliance work riding a genuine regulatory and anti-money-laundering wave, and operating leverage if the cycle actually turns. Fine. Readable.

The bears have the receipts: Protiviti is still declining, down 3%. Contract-staffing growth is "pricing-driven, with underlying volumes still down" — Goldman's words, meaning they're charging more for less actual volume. And there's the uncomfortable detail that RHI has only beaten in two of its last four quarters, with the stock declining after at least one of those beats. Beats don't get rewarded here; the market's been waiting for a trend, and a single quarter of growth isn't a trend.

The Setup, Plainly

Let me lay it out without the noise. This is a well-known staffing company that just reported an okay quarter, guidance that's mildly positive, and then surged to a 52-week high on momentum — not fundamentals. The analyst targets say the stock is overextended. Short float sits at a crowded 19.98%, which is a powder keg in either direction. Goldman, the bears' poster child, still owns its Sell.

I'll be direct about my read: the story's already partly in the price. When a stock runs 22% in a day and every reasonable target sits 15–20% below where it trades, you aren't buying a bargain. You're buying conviction from people who aren't in the target tables. The Q3 report earned the pop. What comes next depends on whether the cycle turns — and if it were about to, you'd expect the analysts to be moving their targets up, not sitting on $30-to-$38 while the tape hits $46.

One more thing worth sitting with before anyone chases this: RHI is reporting Q4 2026 earnings today, October 23. So the tape isn't just digesting a past quarter. It's pricing in the next one at a price near its highs, with guidance already in hand and the sell-side broadly unmoved.

That's not a compelling risk/reward for the optimistic. It's a momentum trade wearing a fundamentals suit. And momentum trades near a 52-week high with a 20% short float don't usually end quietly. Buy it if you must — but know exactly which side of the street you're standing on.